3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione has been researched along with Cancer of Skin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balch, C; Bartolucci, AA; Presant, CA; Troner, M | 1 |
| Bartolucci, AA; Oldham, R; Presant, CA; Ungaro, P | 1 |
1 trial(s) available for 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione and Cancer of Skin
| Article | Year |
|---|---|
A randomized comparison of cyclophosphamide, DTIC with or without piperazinedione in metastatic malignant melanoma.
Topics: Antibiotics, Antineoplastic; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Piperazines; Random Allocation; Skin Neoplasms | 1982 |
1 other study(ies) available for 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione and Cancer of Skin
| Article | Year |
|---|---|
Phase II trial of piperazinedione in malignant melanoma: a report by the Southeastern Cancer Study Group.
Topics: Antibiotics, Antineoplastic; Bone Neoplasms; Drug Evaluation; Humans; Lung Neoplasms; Melanoma; Piperazines; Skin Neoplasms; Thrombocytopenia | 1979 |